- RCEP trade deal negotiators must reject terms that would harm access to medicines
- TPP may be dead – now let’s stop Obama’s other bad trade deals
- After the TPP, what’s next for Australia?
- On World AIDS Day, threat to access to medicines looms large
- Delhi HC sets aside Centre’s decision to ban 344 fixed dose combination drugs
Source: MSF Access Campaign
Geneva/Jakarta, 5 December 2016 – As negotiators from the 16 countries in the Regional Comprehensive Economic Partnership (RCEP) meet in Tangerang, Indonesia, starting today, international medical humanitarian organisation Médecins Sans Frontières (MSF), along with other health groups, reiterated concerns about harmful intellectual property provisions in the proposed agreement that would increase market monopolies for pharmaceutical corporations and delay or block access to affordable generic medicines.
With ratification and implementation of the highly controversial Trans-Pacific Partnership (TPP) trade agreement increasingly in doubt, countries in the Asia-Pacific region are focusing on the RCEP trade agreement, which contains similarly damaging provisions for access to medicines as the TPP.
By Erich Pica, The Huffington Post
After six years of campaigning by international civil society, the Trans Pacific Partnership (TPP) appears to be dead. Yet the TPP is not an isolated one-off agreement; it is part of a dangerous new trade trio that forms a corporate blueprint for the global economy and that threatens workers’ rights and the planet. Continue reading
By Jackson Gothe-Snape | December 2, 2016
The United States has soured on the Trans-Pacific Partnership (TPP) during 2016, disintegrating Australia’s trade strategy and scuppering years of negotiations.
Although President Barack Obama drove development of the agreement, president-elect Donald Trump is vocal in his opposition, saying that he will pull the US out of the TPP “on day one” of his Presidency. Continue reading
By Shailly Gupta, Jakarta Post| December 2, 2016
Today millions of people living with HIV in South-East Asia are receiving treatment and leading healthy lives thanks to affordable generic antiretroviral (ARVs) medicines.
Governments and treatment providers across Asia, such as the government of Indonesia and Médecins Sans Frontières (MSF) patients across our missions in many countries, depend on an uninterrupted supply of affordable generic HIV medicines to reduce new HIV infections and AIDS-related deaths in the region. Continue reading
By Akanksha Jain, The Hindu| December 1, 2016
In a major development and big relief to pharma majors, the Delhi High Court on Thursday set aside the Union government’s decision to ban 344 fixed-dose combination (FDC) drugs, including well known names like Corex, a cough syrup, Vicks Action 500 and D’Cold. Continue reading
Trans-Pacific Partnership (TPP) should not be used as a model for the Regional Comprehensive Economic Partnership (RCEP)*, 316 civil society organisations from across the Asia Pacific have warned as the sixteenth round of negotiations begin this week in Indonesia. Continue reading
The report of the Government-majority Joint Standing Committee on Treaties has predictably endorsed the ratification of the TPP, AFTINET Convener Dr Patricia Ranald said today. Continue reading